Apeximmune Therapeutics is Drug Discovery in United States that focus on technology platform business. Founded in 2016. They cover business area such as developer, novel biologic, bioinformatic, biological assay, identification, novel immune modulating target, disease, these mechanism, client, treatment, indication, cancer, transplantation.
2016
( 8 years old in 2024 )
Technology Platform
-
329 Oyster Point Boulevard
3rd Floor
South San Francisco, CA 94080
United States
Private
developernovel biologicbioinformaticbiological assayidentificationnovel immune modulating targetdiseasethese mechanismclienttreatmentindicationcancertransplantation
* We use standard office opening hours in near Apeximmune Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Apeximmune Therapeutics is Drug Discovery business from United States that founded in 2016 (8 years old in 2024), Apeximmune Therapeutics business is focusing on Technology Platform.
Apeximmune Therapeutics headquarter office and corporate office address is located in 329 Oyster Point Boulevard 3rd Floor South San Francisco, CA 94080 United States.
Apeximmune Therapeutics was founded in United States.
In 2024, Apeximmune Therapeutics is currently focus on technology platform sector.
Above is snippet of Google Trends for "technology platform" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Apeximmune Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
